By Business/Source
Currency:HKD
2025/H1
2025/H1
2024/FY
2024/H1
2023/FY
2023/H1
2022/FY
2022/H1
2021/FY
2021/H1
2020/FY
2020/H1
2016/FY
2016/H1
2015/FY
2015/H1
2014/FY
2014/H1
2013/FY
2013/H1
2012/FY
2012/H1
2011/FY
2011/H1
2009/H1
2008/FY
2008/H1
2007/FY
2007/H1
2006/FY
2006/H1
2005/FY
Stock NameRevenueRatio
生产及销售制药科技产品3.85B62.96%
销售生物技术产品1.68B27.58%
销售核药抗肿瘤诊疗及心脑血管精准介入诊疗科技产品577.74M9.46%
By Product
Currency:HKD
2025/H1
2025/H1
2024/FY
2024/H1
2023/FY
2023/H1
2022/FY
2022/H1
2021/FY
2021/H1
2020/FY
2020/H1
2016/FY
2016/H1
2015/FY
2015/H1
2014/FY
2014/H1
2013/FY
2013/H1
2012/FY
2012/H1
2011/FY
2011/H1
2009/H1
2008/FY
2008/H1
2007/FY
2007/H1
2006/FY
2006/H1
2005/FY
Stock NameRevenueRatio
生产及销售制药科技产品3.85B62.96%
销售生物技术产品1.68B27.58%
销售核药抗肿瘤诊疗及心脑血管精准介入诊疗科技产品577.74M9.46%
By Country/Region
Currency:HKD
2025/H1
2025/H1
2024/FY
2024/H1
2023/FY
2023/H1
2022/FY
2022/H1
2021/FY
2021/H1
2020/FY
2020/H1
2019/FY
2019/H1
2018/FY
2018/H1
2017/FY
2017/H1
2016/FY
2016/H1
2015/FY
2015/H1
2014/FY
2013/FY
2012/FY
2011/FY
2010/FY
2009/FY
2009/H1
2008/FY
2007/FY
2006/FY
2005/FY
Stock NameRevenueRatio
China5.29B86.60%
America373.19M6.11%
Europe229.2M3.75%
Asia (excl. China)184.72M3.02%
Other31.28M0.51%